NEKTAR THERAPEUTICS (NKTR) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$35.75

From 52W high−63.49%

Volume831529.00

Market cap$1.25B

P/E (TTM)—

P/S (TTM)22.9x

Div yield—

Key dataOct 19, 2026

Open

$35.75

From 52W high

−63.49%

Volume

831529.00

Market cap

$1.25B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.2x

P/E (TTM)

—

RSI (14)

22.2

MomentumView details →

1D Return

+2.40%

YTD Return

−14.12%

SummaryUpdated Jun 1, 2026

Nektar Therapeutics (NASDAQ:NKTR) is a San Francisco-based biopharmaceutical company founded in 1990 and publicly traded since 1994. The company focuses on discovering and developing novel medicines for areas of significant unmet medical need, particularly in immunology and oncology. Originally known for its proprietary PEGylation technology platform that enhances drug properties, Nektar has evolved into a clinical-stage biotechnology company with a pipeline of investigational therapies targeting autoimmune diseases and cancer. The company has undergone significant strategic restructuring in recent years, narrowing its focus to core programs while extending its cash runway through facility sales and workforce reductions.

Ask drillr about NEKTAR THERAPEUTICS →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.2x

EV/Sales

12.9x

P/S (TTM)

22.9x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

99.36%

Net Margin

−287.84%

EBITDA Margin

−245.90%

ROE (TTM)

−17.40%

ROA (TTM)

−14.35%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

−27.15%

EPS YoY

+23.08%

FCF YoY

−25.78%

Revenue CAGR 3Y

−15.66%

EPS CAGR 3Y

−12.10%

EBITDA YoY

−53.75%

MomentumView details →

1D Return

+2.40%

YTD Return

−14.12%

1Y Return

−42.36%

RSI (14)

22.2

vs 50D SMA

−41.64%

vs 200D SMA

−44.24%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

10.42x

Quick Ratio

10.42x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.23

EPS Surprise

37.56%

Beats (12Q)

8/12

Next Q EPS Est

−$2.76

Avg Surprise (4Q)

24.03%

Rev Surprise

−2.82%

Financials snapshotView financials →

Revenue (TTM)

54.59M

Net Income (TTM)

−157.13M

Op. CF (TTM)

−233.79M

Next earningsNov 5, 2026 →

Latest newsMore news →

Nektar Therapeutics reported sustained hair regrowth after treatment ended in its hair loss treatment data.19d ago

Nektar Therapeutics and collaborators at the Icahn School of Medicine at Mount Sinai presented new multi-omic biomarker sub-study results from REZOLVE-AD at the EADV Congress 2026, showing early molecular responses to rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.20d ago

Similar companies

LB Pharmaceuticals Inc Common StockLBRX GH Research PLCGHRS ST嘉必优688089.SH Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.02566.HK ImmuneOnco Biopharmaceuticals (Shanghai) Inc.01541.HK Taysha Gene Therapies, Inc.TSHA Find similar companies →

Latest newsMore news →

Nektar Therapeutics reported sustained hair regrowth after treatment ended in its hair loss treatment data.19d ago Nektar Therapeutics and collaborators at the Icahn School of Medicine at Mount Sinai presented new multi-omic biomarker sub-study results from REZOLVE-AD at the EADV Congress 2026, showing early molecular responses to rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.20d ago Nektar Therapeutics announced that data from its Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata will be presented in three oral presentations at the EADV Congress 2026 in Vienna, Austria, and will host an investor conference call on October 1, 2026.22d ago